TT 034

Drug Profile

TT 034

Alternative Names: TT-034

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Benitec Biopharma
  • Developer Tacere Therapeutics
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action Hepatitis C virus replication inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 30 Nov 2016 Tacere Therapeutics completes a phase I/II trial in Hepatitis C in USA (NCT01899092)
  • 26 Feb 2016 Discontinued - Phase-I/II for Hepatitis C in USA (IV)
  • 16 Apr 2015 Benitec Biopharma in-licenses Adeno-Associated Virus (AAV) gene therapy technologies from Asklepios BioPharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top